Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling

Diabetologia

Volumn 49, Issue 9, 2006, Pages 2030-2038

  Clausen, W H O ^a,c   De Gaetano, A ^b   Volund A ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b CNR   (Italy)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Absorption rate; Between subject variation; Clearance; Elimination rate; Insulin pharmacokinetics; Volume of distribution; Within subject variation

Indexed keywords

BIPHASIC INSULIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COMPARTMENT MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SYNTHESIS; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KINETICS; MALE; PRIORITY JOURNAL;

AREA UNDER CURVE; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MODELS, THEORETICAL;

EID: 33746722121     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0327-z     Document Type: Article

References (26)

1. The diabetes control and complications trial research group (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
2. Brange J, Vølund A (1999) Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 35:307-335
3. Lindholm A, Jacobsen JV (2001) Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 40:641-659
4. Kaku K, Matsuda M, Urae A, Irie S (2000) Pharmacokinetics and pharmacodynamics of insulin aspart a rapid-acting analog of human insulin in healthy Japanese volunteers. Diabet Res Clin Pract 49:119-126
5. Chen J-W, Lauritsen T, Christiansen JJ, Jensen LH, Clausen WHO, Christiansen JS (2005) Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with type 1 diabetes: a randomized double-blinded crossover study. Diabet Med 22:273-277
6. Brange J, Ribel U, Hansen JF et al (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682
7. Brange J (1997) The new era of biotech insulin analogues. Diabetologia 40 (Suppl 2):S48-S53
8. Jacobsen LV, Søgaard B, Riis A (2000) Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 56:399-403
9. Vølund A, Brange J, Drejer K et al (1991) In vitro and in vivo potency insulin analogues designed for clinical use. Diabet Med 8:839-847
10. Binder C, Lauritzen T, Faber O, Pramming S (1984) Insulin pharmacokinetics. Diabetes Care 7:188-199
11. Wenk RE (1998) Mechanism of interference by hemolysis in immunoassays and requirements for sample quality. Clin Chem 44:2554
12. Littell RC, Milliken GA, Stroup WW, Wolfmger RD (1996) SAS system for mixed models. Cary, SAS Institute
13. Clausen WHO, Tabanera R, Dalgaard P (2005) Solving the bias problem in pharmacokinetic data. Research Report 05/05. University of Copenhagen, Denmark
14. Goldberg DE (1989) Genetic algorithms in search, optimization, and machine learning. Addison-Wesley, Reading
15. Bates DM, Watts DG (1988) Nonlinear regression analysis and its applications. Wiley, New York
16. R Development Core Team (2004) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, http://www.R-project.org
17. Kang S, Brange J, Burch A, Vølund A, Owens DR (1991) Subcutaneous insulin absorption explained by insulin's physiochemical properties - evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 14:1057-1065
18. Nucci G, Cobelli C (2000) Models of subcutaneous insulin kinetics. A critical review. Comput Methods Programs Biomed 62:249-257
19. Wilinska ME, Chassin LJ, Schaller HC, Schaupp L, Pieber TR, Hovorka R (2005) Insulin kinetics in type 1 diabetes. Continuous and bolus delivery of rapid acting insulin. IEEE Trans Biomed Eng 52:3-12
20. Kobayashi T, Sawano T, Itoh T, Kosaka K, Hirayama H, Kasuya Y (1983) The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients. Diabetes 32:331-336
21. Mosekilde E, Jensen KS, Binder C, Pramming S, Thorsteinsson B (1989) Modeling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 17:67-87
22. Robinson RTCE, Harris, ND, Ireland RH, Lindholm A, Heller SR (2003) Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in cardiac repolarization. Br J Clin Pharmacol 55:246-251
23. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J (2002) Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 25:876-882
24. Heinemann L (2002) Variability of insulin absorption and insulin action. Diabetes Technol Ther 4:673-682
25. Perriello G, De Feo P, Torlone E et al (1991) The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 34:21-28
26. Holl RW, Heinze E (1992) Dawn or Somogyi phenomenon? High morning fasting blood sugar levels in juvenile type 1 diabetics. Deutsche Medizinische Wochenschrift 117:1503-1507 (German)